DV
Dividend Vision

MLTX — MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (MLTX)

Total return is 57.0% over the past 5.8 years, 87.5 points behind SPY at 144.5%. Its deepest 1-year drawdown was 89.9%.

MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing therapies for inflammatory skin and joint diseases, with a focus on Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody candidate for conditions including psoriasis, psoriatic arthritis, and hidradenitis suppurativa. As a pre-revenue biotechnology company, it does not currently distribute dividends. The company appeals to investors with a risk tolerance for early-stage biotech development and those seeking exposure to immunotherapy innovation rather than current income.

MLTX key facts

Asset type
Stock
Asset class
Equity
Inception date
10/20/2020
Distribution frequency
None
Last close
$16.47
Market cap
$1,401,707,136
Average volume
980300.0
Beta
1.068
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.84